Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RMD's robust mask business and efforts to boost its SaaS business are encouraging.

Is ResMed Stock a Smart Addition to Your Portfolio Right Now?

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Earnings Expected to Grow: Should You Buy?

Royal Philips

Investors with an interest in Medical - Products stocks have likely encountered both Royal Philips (PHG) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

PHG or RMD: Which Is the Better Value Stock Right Now?

Agnico Eagle Mines

CRA International

Leidos Hld

NetApp

NetApp (NTAP), Agnico Eagle (AEM), ResMed (RMD), Charles River (CRAI) and Leidos Holdings (LDOS) could be compelling picks in the final quarter of the year.

5 Dividend Growth Stocks to Buy in Q4

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024

Accenture Plc

Amphenol

Domino's Pizza

Elevance Health Inc

Global Payments

Intuit

Mastercard

MSCI

Nordson

NXP Semiconductors

Old Dominion Freight Line

Rollins

SPDR S&P 500 ETF Trust

Visa

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF Trust posted a gain of 2.10% in September as it continues marching on in 2024. The Top 15 dividend growth stocks for October 2024 offer an average dividend yield of 1.05% and appear to be about 20% undervalued based on dividend yield theory.

My Top 15 High Growth Dividend Stocks For October 2024

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ResMed (RMD) Upgraded to Buy: What Does It Mean for the Stock?

Hubbell

Ferrari

Vertex, Inc.

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RACE, VERX, RMD and HUBB are some stocks that hold promise.

Scoop up These 4 GARP Stocks to Receive Handsome Returns

ResMed introduces digital and personalized solutions designed to improve sleep health.

RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions

NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed's plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.

ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns

ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir ™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling.

UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health

UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed results, with improvements in gross profitability and asset turnover but a longer cash conversion cycle. But there were improving returns. The company is financially sound. There is a margin of safety if you assume that there would be another major acquisition next year.

ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety

Major U.S. equities indexes ended lower on Wednesday after the Federal Reserve reduced its benchmark interest rate by half a percentage point. Central bank policymakers opted for an aggressive rate cut as the focus shifts toward economic growth and the employment market following a multi-year campaign to fight inflation.

S&P 500 Gains and Losses Today: ResMed Drops as Weight-Loss Drugs Threaten Demand

An analyst downgraded his recommendation on the medical device specialist. He now feels investors should avoid it.

Why ResMed Stock Tumbled by 5% Today

ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates. Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors.

Why ResMed's Rally Is Just Getting Started

Strong demand for RMD's market-leading mask portfolio raises investors' optimism.

Reasons to Retain ResMed Stock in Your Portfolio for Now

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online.

ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange

Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.

United States Sleep Disorders Treatment Market 2024-2028, with Profiles of Better Night, Koala Centers, Marshall Medical Centers, Novasom, ResMed, Respironics, Sleep Holdings, SleepMed and More

Canadian National Railway Company

NIKE

Sirius XM Holdings Inc

The SPDR S&P 500 ETF Trust posted a 2.34% gain in August, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.32%. The top 15 dividend growth stocks for September 2024 offer an average dividend yield of 1.23% and appear to be about 26% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved a 12.93% annualized return.

My Top 15 High Growth Dividend Stocks For September 2024

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY.

ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Insulet

Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.

S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index

SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board audit committee.

News for ResMed Stock (RMD)